Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland by Siebenhüner, Alexander et al.








Metastatic Colorectal Carcinoma after Second Progression and the Role of
Trifluridine-Tipiracil (TAS-102) in Switzerland
Siebenhüner, Alexander ; De Dosso, Sara ; Meisel, Alexander ; Wagner, Anna Dorothea ; Borner,
Markus
Abstract: BACKGROUND Metastatic colorectal carcinoma (mCRC) is one of the most prevalent types
of cancer worldwide. After tumor progression with first- and second-line treatment, trifluridine (FTD)
and tipiracil (TPI) has been shown to be a treatment option. SUMMARY Data from a pivotal phase 3
trial (RECOURSE) and an ongoing phase 3b trial (PRECONNECT) have shown that, in mCRC patients
who experienced disease progression after 2 lines of standard therapy, treatment with FTD/TPI is safe
and efficacious. Other third-line options include regorafenib, rechallenge with previous treatment lines
or personalized approaches based on comprehensive molecular profiling. Randomized trials or sequential
studies aiming for the right treatment sequence or predefined subtypes for FTD/TPI or regorafenib as
well for rechallenge are missing. However, FTD/TPI as well as regorafenib are recommended by the
current ESMO, German S3, and National Comprehensive Cancer Network (NCCN) guidelines in the
same situation, thus offering physicians a number of alternatives for the treatment of mCRC patients
after the second progression. Key Message: This narrative review summarizes published data and their
impact for FTD/TPI as well for regorafenib and rechallenge chemotherapy in clinical practice settings of
refractory situations of colorectal cancer.
DOI: https://doi.org/10.1159/000506080






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Siebenhüner, Alexander; De Dosso, Sara; Meisel, Alexander; Wagner, Anna Dorothea; Borner, Markus
(2020). Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil
(TAS-102) in Switzerland. Oncology Research and Treatment, 43(5):237-244.
DOI: https://doi.org/10.1159/000506080
Review Article
Oncol Res Treat 2020;43:237–244
Metastatic Colorectal Carcinoma after Second 
Progression and the Role of Trifluridine-Tipiracil 
(TAS-102) in Switzerland
Alexander Siebenhüner a    Sara De Dosso b    Alexander Meisel c    
Anna Dorothea Wagner d    Markus Borner e    
a
 Clinic for Medical Oncology and Hematology, Universitätsspital Zürich and University of Zurich, Zurich, 
Switzerland; b Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland; c Hematology and Oncology, 
Clinic for Internal Medicine, Stadtspital Waid, Zurich, Switzerland; d Département d’oncologie, CHUV, Lausanne, 
Switzerland; e ONCOCARE at the Engeriedspital, Bern, Switzerland
Received: September 8, 2019
Accepted: January 11, 2020
Published online: March 6, 2020
Dr. med. Alexander Siebenhüner




© 2020 The Author(s)





Refractory colorectal cancer · Lonsurf · Trifluridine-tipiracil · 
Tas-102 · Rechallenge · Regorafenib · Second progression
Abstract
Background: Metastatic colorectal carcinoma (mCRC) is one 
of the most prevalent types of cancer worldwide. After tu-
mor progression with first- and second-line treatment, triflu-
ridine (FTD) and tipiracil (TPI) has been shown to be a treat-
ment option. Summary: Data from a pivotal phase 3 trial (RE-
COURSE) and an ongoing phase 3b trial (PRECONNECT) have 
shown that, in mCRC patients who experienced disease pro-
gression after 2 lines of standard therapy, treatment with 
FTD/TPI is safe and efficacious. Other third-line options in-
clude regorafenib, rechallenge with previous treatment 
lines or personalized approaches based on comprehensive 
molecular profiling. Randomized trials or sequential studies 
aiming for the right treatment sequence or predefined sub-
types for FTD/TPI or regorafenib as well for rechallenge are 
missing. However, FTD/TPI as well as regorafenib are recom-
mended by the current ESMO, German S3, and National 
Comprehensive Cancer Network (NCCN) guidelines in the 
same situation, thus offering physicians a number of alterna-
tives for the treatment of mCRC patients after the second 
progression. Key Message: This narrative review summariz-
es published data and their impact for FTD/TPI as well for 
regorafenib and rechallenge chemotherapy in clinical prac-
tice settings of refractory situations of colorectal cancer.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Colorectal cancer (CRC) is the third most common 
type of cancer worldwide, accounting for 10.6% of all can-
cer cases [1]. In Switzerland, about 4,000 new patients are 
diagnosed with CRC every year, which is 11% of all cancer 
diagnoses [2]. The majority of diagnoses are staged in a 
metastatic setting. At that stage most tumors are inoper-
able and systemic treatment is recommended. Generally, 
metastatic colorectal carcinoma (mCRC) patients receive 
multiple lines of therapy during their history of disease 
[3]. However, in Switzerland, management of mCRC is 
challenging, as no Switzerland-specific guidelines for 
mCRC treatment have been established until now. Thus, 
Swiss physicians use international recommendations for 
mCRC as listed in ESMO, German S3, and National Com-
prehensive Cancer Network (NCCN) guidelines, which 
vary in nuances from each other [3–5]. Basically, the es-
tablishment of treatment recommendations with ongoing 
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updates presented in these guidelines has led to an overall 
improvement in the clinical outcome of mCRC patients 
[6]. Different combinations of chemotherapies with or 
without biologicals or monotherapy regimens or even im-
munotherapies based on the molecular profile as well the 
location of the tumor drives the choice of first- and sec-
ond-line treatment regimens for mCRC [3–5]. These 
strategies have resulted in improvement of overall surviv-
al (OS) of mCRC patients, i.e., from 19 months to over 3 
years in the last decade [7]. As mCRC patients tend to live 
longer with the tumor, a larger group of patients should 
be assessed for third or refractory lines of treatment. In 
cases of refractory mCRC that has not responded favor-
ably to first- and second-line treatments, an oral combina-
tion drug, i.e., trifluridine-tipiracil (FTD/TPI, Lonsurf®), 
or an oral multikinase inhibitor, i.e., regorafenib, as well 
as rechallenge of chemotherapy with or without a former-
ly used antibody regimen are valid options presented in 
ESMO and NCCN recommendations [3, 5]. The recom-
mendation level in the guidelines of the NCCN and ESMO 
ranks these options equally, whereas S3 has reassessed the 
ranking of regorafenib with a weaker recommendation 
compared to other options such as FTD/TPI or rechal-
lenge. This mainly affects mCRC patients in Germany as 
regorafenib is not directly available in that country [3–5].
The other oral drug for refractory mCRC is FTD/TPI. 
It is a combination of: (a) the thymidine-based nucleoside 
analog FTD, which has been reported to act through in-
hibition of thymidylate synthase and incorporation into 
the DNA, ultimately leading to DNA damage and cell 
death, and (b) the TPase inhibitor TPI, which prevents 
the rapid degradation of FTD, thus elongating its short 
half-life. As a result, FTD/TPI remains in the body longer 
and can therefore be administered at a lower dose. Since 
the mode of action of FTD/TPI is significantly different 
from that of fluorouracil (5-FU) (Fig.  1), it has been 
shown to have considerable efficacy in 5-FU-refractory 
patients [8]. In June 2015, Servier and Taiho Pharmaceu-
tical obtained an exclusive license for FTD/TPI under the 
name Lonsurf® [9] for Japan, the USA, the EU, and Swit-
zerland. It has been licensed for adult mCRC patients who 
have already been treated with available first- and 
 second-line therapies such as fluoropyrimidine (5-FU/
capecitabine)-, oxaliplatin- and irinotecan-based chemo-
therapy and anti-VEGF therapy and for RAS wild-type 
mCRC patients treated with anti-EGFR therapy [3–5].
Studies Favoring FTD/TPI Treatment for mCRC 
Patients
A preliminary analysis of the data from the ongoing 
multicenter phase 3b study PRECONNECT, designed to 
evaluate the safety and efficacy of FTD/TPI in real-life 
conditions, confirms the advantages of FTD/TPI as a fa-
vorable treatment for refractory mCRC [10]. A prelimi-
nary analysis of data from 462 patients showed that pa-
tients on FTD/TPI had a median progression-free surviv-
al (PFS) of 2.8 months, disease control was achieved in 
37% of the patients, and their performance status deterio-
rated to ECOG performance status ≥2 after a median of 
only 8.7 months [10]. The safety profile of the therapy was 
acceptable and consistent with that found in the RE-
COURSE study – a pivotal phase 3 trial comparing the ef-
ficacy of FTD/TPI to that od placebo for the treatment of 
refractory CRC and mCRC in heavily pretreated patients 
(ECOG performance status 0–1) [11, 12]. The RECOURSE 
study demonstrated that FTD/TPI treatment successfully 
prolonged the median OS by about 2 months (Fig. 2) and 
PFS (2 vs. 1.7 months) with an acceptable toxicity profile 
[11, 12]. The most frequently observed side effects with 
FTD/TPI were neutropenia (32.4%), asthenia (24.3%), 
anemia (21.6%), and diarrhea (18.9%) [12]. A retrospec-
tive analysis showed that neutropenia could be a good sur-
rogate marker for adequate dose exposure [13]. Further-
more, all of the subgroups in the patient data set, including 
the geographical subsets, the KRAS mutation-based sub-
sets, etc., benefited from FTD/TPI treatment [11, 12]. A 
number of phase 1/2 studies have also shown that the 
combination of FTD/TPI and bevacizumab can lead to a 
positive clinical outcome. A recent study demonstrated 
that the addition of bevacizumab to an FTD/TPI treat-
ment regimen had a tolerable toxicity profile and led to a 
prolonged median PFS (from 2.6 to 5.9 months, 95% CI 
0.28–0.92; p < 0.03) and median OS (from 7.3 to 10.3 
months, 95% CI 0.18–0.99; p < 0.05) [14]. This study was 
inspired by a phase 1/2 multicenter Japanese study (C-
TASK FORCE), which also showed similar results [15]. 
Neutropenia (72%) and leucopenia (44%) were the most 
common adverse effects observed in this study [15]. Fur-
thermore, a phase 2 trial, i.e., RAMTAS, is currently as-
sessing the efficacy of the combination of an anti-VEGFR 
antibody, ramucirumab, and FTD/TPI [16].
Several compassionate use programs of FTD/TPI 
across Europe, the USA, and Asia have been conducted 
and in summary they underline the efficacy and safety of 
FTD/TPI in a real-world population with refractory 
mCRC [17–21].
Rechallenge Therapy: an Alternative after a Second 
Progression
Rechallenge therapy, i.e., administration of a previous-
ly given regimen of chemotherapy with or without the 
same antibodies (e.g., bevacizumab or anti-EGFR related 
to a molecular tumor profile), may be an option for se-
lected patients [22].
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A possible explanation for the efficacy of such a rechal-
lenge strategy is that mCRC comprises heterogeneous tu-
mor clones. Therefore, the first- and second-line treat-
ment do not entirely address this heterogeneity. Even 
clones that were suppressed do not completely disappear 
during the initial treatment and can initiate disease pro-
gression at a later point. Since the number of cytostatic 
agents available for mCRC therapy is limited, resumption 
of treatment with the same chemotherapeutic agents can 
represent a treatment continuum.
This rechallenge concept especially attracts the situa-
tion if more than 6 months have elapsed since the last use 
of this specific regimen. In a prospective study with 
mCRC patients who presented, at the first stage, a re-
sponse to aEGFR but developed resistance over time were 
rechallenged with the aEGFR antibody cetuximab plus 
irinotecan in the refractory setting [23]. Several other 
studies like OPTIMOX 2, COIN, or NORDIC IV under-
line the concept of rechallenge even using a different che-
motherapy backbone in these patients [24]. Interestingly, 
these highly selected patient benefit from this third-line 
strategy. A precondition is that no RAS or BRAF mutation 
was detected by liquid biopsy prior to rechallenge therapy 
[25].
The fact that a median OS of up to 18 months was 
achieved in the REVERSE study [26] – which is long- 
er than that observed after treatment with licensed sec-
ond-line treatments such as aflibercept-FOLFIRI [27] – 
strongly supports the idea that this is a highly selective 
patient group. A benefit of rechallenge with an anti-EGFR 
antibody was demonstrated by biomarkers and evidence 
of the EGFR wild-type clone [25]. Moreover, excellent re-
Fig. 1. Mechanism of action of FTD/TPI. 
FTD/TPI shows a different mechanism of 
action compared to 5-FU-based fluoropy-
rimidines. Adapted from Lenz et al. [8].
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Fig. 2. OS of refractory mCRC patients. Patients treated with FTD/TPI showed a clear OS advantage compared 
to the placebo group. All of the patients showed a benefit from the treatment apart from those who had only 2 
prior regimens. Adapted from Mayer et al. [12].
Treatment Landscape in mCRC After 
Second Progression
241Oncol Res Treat 2020;43:237–244
DOI: 10.1159/000506080
sponse rates (i.e., 21%) and disease control rates (i.e., 
54%) were reported in the CRICKET study, but the me-
dian PFS was relatively short (i.e., 1.9 months in RAS-
mutated patients and 3.9 months in KRAS wild-type pa-
tients) [25].
Rechallenge with oxaliplatin in mCRC can be an op-
tion in the refractory setting that can achieve tumor con-
trol, PFS, and OS benefits [28, 29]. In this setting, how-
ever, patients should be monitored carefully for neuro-
toxicity, hypersensitivity, and allergic reactions [28]. 
Rechallenge with an oxaliplatin-based chemotherapy can 
therefore represent an option for the treatment of refrac-
tory mCRC and it is therefore listed in the joint ESMO 
[3], German S3 [4] and NCCN [5] guidelines. Rechal-
lenge with a chemotherapy combination such as FOL-
FOX or FOLFIRI, however, has not been studied prospec-
tively [22].
Overall, the evidence for the success of a rechallenge 
strategy with cetuximab or bevacizumab with or without 
chemotherapy such as oxaliplatin and irinotecan is lim-
ited. The results of such studies must be interpreted with 
caution due to the small sample sizes and a lack of appro-
priate controls [22]. Further prospective clinical trials are 
warranted before this option can routinely be considered 
in clinical practice. Factors that support the rechallenge 
strategy in mCRC patients are a long duration of response 
to a first-line anti-EGFR therapy, a good general perfor-
mance status, the duration of the treatment response in 
the second line and an interval of at least 6 months be-
tween the first anti-EGFR therapy and the anti-EGFR re-
challenge. However, molecular retesting is recommended 
for anti-EGFR re-challenge therapy. In addition, a posi-
tive effect on PFS was observed only in KRAS wild-type 
patients [25].
To date, there has been no direct comparison between 
rechallenge with a chemotherapy doublet and FTD/TPI 
or regorafenib. However, recent data suggest that the 
timely use of FTD/TPI or regorafenib in early phases of 
refractory mCRC is superior to renewed exposure to a 
chemotherapy doublet or anti-EGFR therapy with regard 
to the time to treatment failure and OS duration [22]. 
Furthermore, FTD/TPI and regorafenib were evaluated 
in large-scale phase 2 and 3 studies in mCRC after a sec-
ond progression. Thus, these treatment options are now 
the preferred choice after a second progression and 
should be given prior to rechallenge therapy [22]. More-
over, a randomized phase 2 study compared cetuximab 
with regorafenib after prior treatment with fluoropyrim-
idines, irinotecan, and oxaliplatin [26]. This sequential 
treatment regimen resulted in a markedly longer OS 
compared to that of the reverse sequence (17.4 vs. 11.6 
months, HR = 0.61) [26]. Apart from the danger of dete-
rioration of the performance status over time, these re-
sults indicate that regorafenib and, by analogy, FTD/TPI 
should be used prior to rechallenge therapy with cetux-
imab.
Fig. 3. Toxicity comparison between FTD/
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The Safety and Quality-of-Life Profiles of FTD/TPI 
and Regorafenib Impact Treatment Decisions
Currently, there are only limited data available on the 
optimal therapy sequence involving FTD/TPI and rego-
rafenib. The key question is whether FTD/TPI or rego-
rafenib should be administered first, and this was inves-
tigated indirectly in PRECONNECT [10, 30]. A post hoc 
subgroup analysis showed that the sequence of treatment 
with FTD/TPI and regorafenib did not affect the efficacy 
of the following treatment regimen [30]. In addition, 
there is no evidence to suggest that either of the 2 treat-
ment options leads to better efficacy. Recent data from 
the RETAS study confirms that both agents can be ad-
ministered in sequence [31]. Without a direct head-to-
head comparison, the sequence of administration re-
mains a clinical decision.
The authors of the PRECONNECT study concluded 
that the safety and quality-of-life profiles are important 
aspects to be considered when treating mCRC patients 
after a second progression. It is important to note that 
FTD/TPI has presented a favorable toxicity profile in 
comparison to regorafenib [30]. This also enables pa-
tients to receive further treatment lines in future.
With FTD/TPI, toxicities in the first 1–2 months are 
mostly hematological. For instance, neutropenia, anemia, 
and thrombocytopenia can occur quickly. In a study by Kasi 
et al. [32], it was observed that neutropenia induced by 
FTD/TPI treatment was associated with a better prognosis 
in patients with refractory mCRC. Thus, the extent of neu-
tropenia in such patients can be instrumental in dose ad-
justments as well as in predicting treatment outcomes [32]. 
Toxicities associated with regorafenib, on the other hand, 
can be more severe (Fig. 3). Regorafenib is mostly associ-
ated with hand-and-foot syndrome, fatigue (which also 
might be observed after treatment with FTD/TPI, but in a 
milder form), liver toxicity, and hypertension. As these 
complaints usually occur in the first 1–2 weeks, patients on 
regorafenib need to visit the clinic once a week during the 
first month. Patients exhibiting pronounced fatigue at this 
stage should be monitored regularly [33].
Another factor affecting treatment decisions after a 
second progression is the impact of treatment on the 
quality of life of the patient. The PRECONNECT study 
shows that more than 20% of patients receiving FTD/TPI 
had improved EORTC Quality-Of-Life Core Question-
naire Core-30 (QCQ-C30) scores, and more than half of 
the patients (58.5%) showed no deterioration in their 
quality of life [34]. Furthermore, the ECOG performance 
status was maintained after treatment with FTD/TPI 
compared to placebo [2, 10–12, 30]. With regorafenib, 
clinical studies have demonstrated that the quality of life 
did not deteriorate in patients treated with regorafenib 
compared to placebo [22, 33].
Various Aspects to be Considered and Individualized 
Concepts
As the treatment options for mCRC patients are evolv-
ing rapidly, several guidelines [3–5] recommend discussing 
the available treatment approaches within a multidisci-
plinary tumor board (MDT) consisting of experts in their 
field of treatment. This could also include individualized 
concepts. For oligometastatic liver disease, for instance, 
ESMO guidelines list various ablative modalities like stereo-
tactic ablative body radiotherapy and radiofrequency abla-
tion as well as hyperthermic intraperitoneal chemotherapy 
for peritoneal disease, and nodal dissection. Surgical proce-
dures have also been expanded beyond the resection of 
maximally 3 liver metastases by novel methods like 2-step 
associating liver partition and portal vein ligation for staged 
hepatectomy (ALPPS) for highly selected cases after discus-
sion in an MDT. These scenarios highlight the complexity 
of an individualized concept using surgical or intervention-
al steps in addition to the systemic options [3].
Tumor heterogeneity and clonal evolution add to the 
complexity of treating refractory mCRC. Therefore, rebi-
opsy of the primary or metastases should be considered 
[25, 35]. However, this will rather be a topic of future 
clinical trials and not part of clinical routine as the thera-
peutic consequences are still unclear.
After anti-EGFR regimens have been exhausted in RAS 
wild-type mCRC, extended molecular testing should be 
taken into account at the latest in the refractory setting. 
Currently several commercial platforms are available for 
comprehensive tumor profiling, which detects various 
subtypes within a certain tumor entity. For mCRC the 
available molecularly driven therapies include BRAF- and 
Her-2-directed therapies as well as immune checkpoint 
inhibition for DNA-mismatch-repair-deficient tumors as 
well rare mutations (e.g., POLE mutations). This extended 
molecular testing might also uncover very rare but highly 
targetable mutations or alterations like NTRK fusions 
which allow treatment with highly selective drugs like en-
trectinib or larotrectinib [36]. Within ongoing trials con-
sidering early use of targeted treatments like BRAF-mu-
tated mCRC, extended molecular testing will be more fo-
cused on the primary diagnosis of mCRC in the future. In 
summary, treatment of mCRC will be become more com-
plex in the future and, besides an MDT, treatment possi-
bilities including expanded molecular profile testing 
should be discussed in a molecular tumor board.
Future Perspectives
A variety of treatment options depicted in the different 
guidelines are currently available to physicians treating 
patients with mCRC. While the development of these 
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treatment options has improved the overall clinical out-
come for such patients, the lack of a definitive and well-
established treatment recommendation represents a chal-
lenge for physicians. Especially for Swiss oncologists this 
is a relevant factor, as there are no Swiss-specific guide-
lines for the management or treatment of mCRC in Swiss 
patients that also includes the availability of these drugs in 
the country as well regulatory affairs. This might be coun-
terproductive for prolongation of OS or for improvement 
of general clinical outcomes for patients. The relevance of 
creating Switzerland-based recommendations regarding 
treatment sequences in relation to clinical, tumor biologi-
cal, and regulation-based factors is of high interest.
Furthermore, an alternative approach would be to 
combine FTD/TPI with rechallenge therapy as a treat-
ment option after a second progression. The APOLLON 
study evaluated the combination of FTD/TPI with an an-
ti-EGFR antibody and this led to considerable improve-
ment in the PFS (5.8 months) and response rate (37%) 
with an acceptable safety profile [37]. However, this study 
had a limited data set as it included only patients without 
prior anti-EGFR treatment. Although the result appears 
promising, further analysis will be needed before a conclu-
sion can be drawn on this combinatorial approach [37].
Conclusions
Treatment of mCRC in refractory settings remains a 
challenging field, with several options such as FTD/TPI, 
regorafenib, and rechallenges equally recommended in 
the updated guidelines [4, 5, 22]. There is currently no 
evidence to suggest a better efficacy of either treatment. 
However, tolerability and the quality of life of patients are 
also important factors to consider when choosing a treat-
ment option after a second progression. Toxicity and im-
pact on quality of life assessments for either regorafenib 
or FTD/TPI treatment options have shown that FTD/TPI 
has a favorable safety profile. Neither of the 2 treatments 
has any impact on the quality of life of the patient.
The strategy of giving FTD/TPI or regorafenib prior to 
rechallenge therapy allows for as many treatment lines as 
possible to achieve the maximal prolongation of OS in the 
patients [3, 4]. Based on the conducted studies FTD/TPI 
or regorafenib may be chosen earlier, although most of 
the study patients were treated after failure of at least 2 
treatment lines. Rechallenge therapy, on the other hand, 
may be given in highly selected cases, i.e., in RAS wild-
type patients who have shown a sustained benefit of ther-
apy in an earlier line with disease control.
However, there is still a need for innovative treatments 
to supplement the currently available options. Moreover, 
new biomarkers are needed to facilitate the development 
of more tailored treatments to match individual patient 
needs. Such biomarkers will also play an important pre-
dictive role to better guide physicians in choosing the 
most effective treatment regimen. Lastly, study models 
can potentially determine the optimal treatment sequence, 
as large randomized studies will hardly be feasible for de-
termining the most effective sequence of treatments.
In conclusion, FTD/TPI and regorafenib provide sim-
ilar advantages in the treatment of refractory mCRC.
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